FindTrial
Sign In

Pembrolizumab/Vibostolimab Co-Formulation

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

CholangiocarcinomaEndometrial NeoplasmsEsophageal NeoplasmsGallbladder NeoplasmsHepatocellular CarcinomaOvarian NeoplasmsSmall Cell Lung CarcinomaSquamous Cell Carcinoma of Head and Neck

Phase 2

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
CompletedNCT05007106
Merck Sharp & Dohme LLCCholangiocarcinoma, Endometrial Neoplasms, Esophageal Neoplasms +8
Start: 2021-09-16End: 2025-08-05Updated: 2025-08-14

Phase 3

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Active, not recruitingNCT05224141
Merck Sharp & Dohme LLCSmall Cell Lung Carcinoma
Start: 2022-03-24End: 2027-06-07Updated: 2025-07-08

Related Papers

Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
Journal of Clinical Oncology2024-06-014 citations
22O Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): Exploratory analysis from the phase II KEYVIBE-005 study
ESMO Open2024-06-012 citations
25P Patient-reported outcomes (PROs) with coformulated vibostolimab/pembrolizumab (vibo/pembro) for metastatic cervical cancer (CC): Results from the KEYVIBE-005 study
ESMO Open2024-06-01
21O Coformulated vibostolimab/pembrolizumab in advanced cervical cancer: KEYVIBE-005
ESMO Open2024-06-01
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
2024-02-01
Abstract CT129: A multicohort, open-label, phase 2 basket study of the coformulation of vibostolimab with pembrolizumab, with or without other anticancer therapies, in select solid tumors
Cancer Research2022-06-15
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
Journal of Clinical Oncology2022-06-018 citations